Journal
ANNALS OF HEMATOLOGY
Volume 98, Issue 1, Pages 73-81Publisher
SPRINGER
DOI: 10.1007/s00277-018-3480-9
Keywords
Acute myeloid leukemia; Allogeneic hematopoietic stem cell transplantation; Minimal residual disease; CBF; MYH11 gene
Categories
Funding
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81621001]
- National Natural Science Foundation of China [81670175]
- Scientific Research Foundation for Capital Medicine Development [2016-1-4082]
- Beijing Key Laboratory for Hematopoietic Stem Cell Transplantation
Ask authors/readers for more resources
Ninety acute myeloid leukemia (AML) patients with inv(16) were monitored CBF/MYH11 transcript around allogeneic hematopoietic stem cell transplantation (allo-HSCT). A total of 23 patients received HLA-matched sibling donor transplantation (MSDT) and 67 patients received unmanipulated haploidentical hematopoietic stem cell transplantation (haplo-HSCT) were analyzed in this study. Patients were divided into four groups based on CBF/MYH11 expression prior to transplantation (pre-MRD): with negative (group 1)/positive (group 2) pre-MRD before MSDT; with negative (group 3)/positive (group 4) pre-MRD before haplo-HSCT. The results showed that patients in group 2 had the highest cumulative incidence of relapse (2-year CIR, 40.7%), the lowest leukemia-free survival (2-year LFS, 50.8%), and overall survival (2-year OS, 62.5%). The other three groups of patients had comparable outcomes. The patients were also classified into the other three groups according to CBF/MYH11 value of +1month after transplantation: group 5: pre- and post-transplant MRD were both negative; group 6: the value of post-transplant MRD was lower than 0.2%; group 7: the value of post-transplant MRD was higher than 0.2%. Group 7 had the highest CIR and the lowest LFS. These results indicated that AML patients with inv(16) were able to be separated into high-risk and low-risk relapse groups based on peritransplant MRD determined by RQ-PCR-based CBF/MYH11. Haplo-HSCT might overcome the negative impact of pre-MRD on patient outcomes compared to MSDT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available